Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Kura’s President & CEO Troy Wilson sat down with Precision Medicine Online to discuss the latest data from the KOMET-007 clinical trial for patients with acute myeloid leukemia (AML).

Kura shared preliminary data on its menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), for people with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) AML.

In this article, Troy shares why this data is encouraging for patients, and what stakeholders can expect next for ziftomenib as both a monotherapy and combination therapy.

Read Precision Medicine Online’s full coverage and the press release with the full data below: